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Abstract
In yeast, the G1 cyclin Cln3 promotes cell cycle entry by activating the transcription factor SBF. In mammals, there is a
parallel system for cell cycle entry in which cyclin dependent kinase (CDK) activates transcription factor E2F/Dp. Here we
show that Cln3 regulates SBF by at least two different pathways, one involving the repressive protein Whi5, and the second
involving Stb1. The Rpd3 histone deacetylase complex is also involved. Cln3 binds to SBF at the CLN2 promoter, and
removes previously bound Whi5 and histone deacetylase. Adding extra copies of the SBF binding site to the cell delays
Start, possibly by titrating Cln3. Since Rpd3 is the yeast ortholog of mammalian HDAC1, there is now a virtually complete
analogy between the proteins regulating cell cycle entry in yeast (SBF, Cln3, Whi5 and Stb1, Rpd3) and mammals (E2F, Cyclin
D, Rb, HDAC1). The cell may titrate Cln3 molecules against the number of SBF binding sites, and this could be the
underlying basis of the size-control mechanism for Start.
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Introduction
The budding yeast Saccharomyces cerevisiae commits to cell-cycle
entry at a point called ‘‘Start,’’ equivalent to the restriction point in
animals. Start depends on cell growth to critical size [1–5]. At the
molecular level, Start coincides with and depends on a Start-
specific burst of transcription of over 100 genes including the G1
cyclins CLN1 and CLN2, the S-phase cyclins CLB5 and CLB6, and
many genes for budding and DNA synthesis [6,7]. The burst of
transcription at Start depends on two closely related transcription
factors SBF and MBF, each of which contains the transcriptional
modulator Swi6, and a sequence-specific DNA binding protein,
Swi4 in SBF, and Mbp1 in MBF [8]. SBF is most important for
the transcription of CLN1 and CLN2, and these G1 cyclins are
most important for propelling the cell cycle forward. SBF is found
bound to the CLN1 and CLN2 promoters in early G1, well before
Start, but at this time does not induce any transcription [9–12].
Indeed, in early G1, SBF may repress transcription. When cells
have grown to critical size, the SBF is somehow converted to a
transcriptional activator, and induces transcription of many genes
including CLN1 and CLN2.
The G1 cyclin Cln3, in combination with the cyclin dependent
kinase Cdc28 (or Cdk1), is a key regulator of Start [13,14], and is
critical for the size-dependent activation of SBF and MBF [7],
converting them from their early G1 repressive forms into the late
G1 activating forms. Consistent with the idea that CLN3 is a critical
activator of Start, hyperactive alleles of CLN3 (e.g., WHI1-1), and
over-expression of CLN3, accelerate Start to smaller cell sizes,
whereas deletion of CLN3 delays Start to much larger cell sizes
[13,14]. A cln3 null mutant, despite having a delayed Start and large
cells, is viable because there are alternative methods of inducing
transcription of CLN1 and CLN2. The most important alternative
route depends on the mysterious gene BCK2. The mechanism by
which the Bck2 protein activates CLN1 and CLN2 transcription is
still largely unknown [15,16]. A cln3 bck2 mutant is inviable in most
genetic backgrounds precisely because it does not express sufficient
amounts of CLN1 or CLN2, and inviability can be suppressed by the
expression of CLN2 from a heterologous promoter [17,18].
An obvious model for the CLN3-dependent activation of SBF is
that the Cln3-Cdc28 kinase complex might phosphorylate SBF,
thus activating it. However, no evidence for this model has been
found [19]. Instead, there has been an accumulation of evidence
that Cln3 works, at least in part, by inhibiting a repressor of SBF.
Costanzo et al. and de Bruin et al. have identified Whi5 as one
such repressor [20,21]. The Whi5 protein associates with SBF on
the CLN2 promoter to repress transcription, and Cln3-Cdc28
phosphorylates and antagonizes Whi5 [20,21]. Furthermore,
deletion of WHI5, like over-expression of CLN3, accelerates Start
to smaller cell sizes [22], and the whi5 null mutant suppresses the
inviability of the cln3 bck2 double mutant [20,21].
Although Whi5 is clearly an important target of Cln3, and an
important regulator of SBF, it may not be the only target.
PLoS Biology | www.plosbiology.org 1 September 2009 | Volume 7 | Issue 9 | e1000189Costanzo et al. found some evidence that whi5 null mutants were
still responsive to CLN3, suggesting that CLN3 was also acting by at
least one alternative pathway.
An enduring mystery has been the link between cell size and the
activation of SBF. Cln3-Cdc28 activates SBF only when cells have
grown to a critical size. But Cln3-Cdc28 is present even in very
small cells. At least in slowly growing G1 cells, Cln3 abundance
increases through G1 as the cell grows more-or-less in proportion
to cell size and total cell protein. That is, its absolute abundance
increases, but its relative abundance (relative to cell volume, or
relative to protein content) does not, or at least not by very much
[7,23]. How does a small increase in abundance trigger Start at a
critical size? One possibility is that Cln3 is titrated against
something that is constant per cell. Here, we suggest that
increasing amounts of Cln3 are titrated directly against the SBF
bindings sites in genomic DNA, which are of course constant in
number through G1 phase. At a sufficiently high Cln3/SBF site
ratio, SBF is activated, and Start ensues.
Finally, it is remarkable how well eukaryotic cell cycle control
mechanisms have been conserved, with the functional replacement
of fission yeast cdc2 by human cdc2 (CDK1) [24] an early and
striking example. The yeast system for promoting Start is
analogous and perhaps homologous to the mammalian system,
with SBF, Cln3, and Whi5 playing roles similar to those of E2F-
Dp, Cyclin D, and Rb, respectively [25]. Our results suggest that
the analogy goes even deeper, with both the yeast and mammalian
system making critical use of the Rpd3 histone deacetylase to
repress transcription of S-phase genes.
Results
Whi5 Is Not the Sole Target of Cln3
The only known role of Cln3 is to activate SBF and MBF;
evidence for this is that swi6 mutants (which lack both SBF and
MBF) are completely nonresponsive to CLN3 [19]. That is, the cell
size of swi6 mutants is unaffected by over-expression or under-
expression of CLN3. If Whi5 is the one and only target of Cln3,
then the size of whi5 mutant cells, like that of swi6 mutant cells,
should also be nonresponsive to CLN3. Whether or not this is true
is unclear, although Costanzo et al. [20] found some evidence that
whi5 mutants did respond to CLN3.
To address this issue in a more sensitive way, we used strains
containing a bck2 mutation. Since Bck2 is a redundant with Cln3
for expression of CLN1, CLN2, and other genes [17,18], bck2
mutants are even more sensitive than wild-type cells to the effects
of CLN3. Thus we compared bck2 WHI5 cells with bck2 whi5 cells
with respect to the effect of CLN3 on cell size. Results (Figure 1,
top two panels) show clearly that both genotypes are still
responsive to CLN3. Thus, Cln3 can affect cell size, and
presumably SBF/MBF activation, even in a whi5 null strain,
suggesting it has some target in addition to Whi5.
A Screen for Additional Repressors of SBF
As described above, a cln3 bck2 double mutant is inviable in
many strains, because SBF cannot be activated, and so CLN1,
CLN2, CLB5, and CLB6 cannot be expressed at sufficient levels.
However, a whi5 mutation relieves some of the repression of SBF,
and so a cln3 bck2 whi5 mutant is viable.
Mutations in other putative repressors of SBF might also
suppress the inviability of a cln3 bck2 strain. Thus we constructed a
cln3 bck2 strain kept alive by plasmid-borne MET-CLN2 (a
construct where CLN2 expression is repressed by methionine).
This strain is viable in the absence of methionine, but dies with a
G1 arrest in the presence of methionine. The strain was
mutagenized using a transposon library (so that mutant genes
could be identified), and spread on +met plates to select
suppressors.
This screen yielded two classes of mutants irrelevant to our
studies. First, there were a variety of mutants (many cis-acting) that
derepressed the MET promoter, and thus mis-expressed the
plasmid-borne MET-CLN2. Second, there were mutants that by
one means or another increased the expression of the RME1 gene,
which encodes a transcription factor that, among other things,
binds directly to the CLN2 promoter and increases CLN2
expression [26]. We identified these irrelevant mutants using
secondary screens; they were not further analyzed.
The screen also yielded four complementation groups that may
be of direct relevance: chd1, hda2, pho23, and stb1. The chd1 and
stb1 mutations were obtained many times each, whereas hda2 and
pho23 were obtained only once each. No whi5 mutation was
obtained, but subsequent examination of the mutagenic transpo-
son library by PCR showed that this library did not contain even
one disrupted copy of WHI5.
CHD1 is CHromoDomain 1, a nucleosome remodeling factor
containing a chromodomain, (which can mediate binding to
histones bearing methylated lysines), a helicase domain, and a
DNA binding domain [27]. It is a component of both the SAGA
and SILK complexes [27]. It is a likely mediator of SBF activity,
but its relevance will be considered in a separate report.
Interestingly, Rb-binding protein 1 (RBP1), a mediator of E2F
repression in mammalian cells, also contains a chromodomain.
HDA2 is Histone DeAcetylase 2, a member of the Hda1 histone
deacetylase complex [27]. Its function is poorly understood.
Although we do not further consider Hda2 here, it could well be a
repressor at the CLN2 promoter.
PHO23 encodes a component of the Rpd3 histone deacetylase
complex [28]. The Rpd3 histone deacetylase is a major histone
deacetylase activity in yeast [29,30], and moreover is the yeast
ortholog of mammalian HDAC1, the histone deacetylase that
interacts with E2F and Rb.
Finally, STB1 (Sin Three Binder 1) was originally isolated as an
interactor with Sin3 [31], and Sin3 is a targeting subunit for the
Rpd3 histone deacetylase [32]. Stb1 has also been isolated as a
protein binding to the Swi6 component of SBF and MBF, and
modulating transcription [33,34]. Thus Stb1 could be a link
between SBF and the Rpd3 histone deacetylase complex.
The involvement of both Stb1 and Pho23 implicated the Rpd3
histone deacetylase complex at the CLN2 promoter. Furthermore
Author Summary
Cells seem to divide only after they have grown ‘‘big
enough.’’ Entry into the cell cycle, at a point called Start in
budding yeast, is triggered by activation of the Cln3 cyclin-
dependent kinase (CDK), which in turn activates down-
stream transcription. We find that the Cln3-CDK acts
through a histone deacetylase, as well as through the
previously discovered repressor Whi5, to activate the SBF
transcription factor and trigger entry into the cell cycle.
The system is strikingly similar to the one in mammalian
cells, which relies on Cyclin D, CDK, the transcription factor
E2F, its repressor Rb, and the histone deacetylase system.
There is preliminary evidence that as the yeast cell grows
in size, the increasing number of Cln3 molecules is titrated
against the fixed number of Cln3-CDK-SBF binding sites in
genomic DNA, and that this cell size-dependent titration
could be the mechanism that makes cell cycle entry
dependent on cell size.
Control of Start by Cln3
PLoS Biology | www.plosbiology.org 2 September 2009 | Volume 7 | Issue 9 | e1000189Figure 1. Responsiveness to CLN3. Various mutants containing bck2 and CLN3 under the control of the GAL promoter (GAL-CLN3) as the only
allele of CLN3 were grown in YEP raffinose medium (CLN3 off, solid grey line), split into two aliquots, and galactose was added to one aliquot (CLN3
on, dotted black line). Cell volume distributions were measured with a Coulter Channelyzer (left column), and photomicrographs were taken (right
two columns). The median cell size (fl) as measured by the Coulter Channelyzer is shown in the bottom left corner of each photograph, and the
percentage budding is shown in the bottom right corner. A shift to smaller cell sizes and to higher percent budding in galactose shows
responsiveness to CLN3. The changes in budding are statistically significant at the p,0.01 level for all strains except the whi5 stb1 strain (4th from top)
and the whi5 sin3 strain (5th from top). The cell size distribution is not shown for GAL-CLN3 bck2 cells in raffinose (top panel) because these extremely
large cells are off-scale. Strains used, from top to bottom, are: LC517, LC520, LC518, LC504, LC524, LC521, and LC523.
doi:10.1371/journal.pbio.1000189.g001
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repression of various cell cycle genes, especially SBF or MBF
dependent genes [35,36]. Therefore we asked whether mutations
in RPD3 (encoding the catalytic subunit) or SIN3 (encoding the
targeting subunit) could, like mutations in STB1, PHO23,o r
WHI5, suppress the inviability of the cln3 bck2 double mutant.
Indeed, both rpd3 and sin3 did suppress the inviability of the cln3
bck2 mutant (Figure 2). Consistent with this, D. Huang, S.
Kaluarchchi, and B. Andrews (personal communication) have also
found that rpd3 can suppress the cln3 bck2 double mutant. As
judged by growth rate of the various mutants (Figure 2), whi5 is the
strongest suppressor.
Because RME1 slightly activates CLN2 transcription directly,
and because one class of suppressor over-expressed RME1,w e
wondered about the relationship, if any, between pho23, sin3, rpd3,
etc., and RME1. Therefore we analyzed the suppressors (chd1,
pho23, stb1, sin3, rpd3, and whi5)i ncln3 bck2 strains that were either
RME1 or rme1. In the RME1 background, all the suppressors could
suppress inviability, and could lose the MET-CLN2 plasmid. In the
rme1 background, the suppressors could again suppress inviability
of the cln3 bck2 MET-CLN2 strain on +met plates; however, strains
of these genotypes could not lose the MET-CLN2 plasmid (with the
whi5 strain being an exception, and able to lose the plasmid). This
result suggested that the slight, residual expression from the
repressed MET-CLN2 construct was important for viability.
The inability of the suppressed rme1 strains to lose the MET-
CLN2 plasmid meant there were two possible explanations for the
suppression. First, it could be that some or all of the suppressors
de-repressed the native, genomic CLN2 locus, allowing viability,
but that the degree of de-repressed CLN2 expression was modest,
and viability also required a trace of additional expression, which
could come either from RME1 (driving genomic CLN2), or from
repressed MET-CLN2 (expressing low, residual levels of CLN2).
Second, it could be that some or all of the suppressors were
activating RME1 (thereby inducing native CLN2) and also de-
repressing MET-CLN2.
Two lines of experimentation showed that the first possibility is
correct. First, the transcript from the native CLN2 locus differs in
length from the MET-CLN2 transcript. We used quantitative (q)
PCR to show that the suppressors increase transcription of the
native CLN2 locus, but have no effect on transcription of MET-
CLN2 (Figure 3). The two strongest suppressors, stb1 and whi5,
activated CLN2 transcription to similar extents (Figure 3).
Expression of CLN1 was also increased. Second, we integrated a
second copy of CLN2 at the CLN2 locus, using a large restriction
fragment that included sequences up to and including the flanking
genes. The tested suppressors (sin3, stb1, and whi5) were able to
suppress inviability of the resulting cln3 bck2 rme1 26CLN2 strain,
and these strains were able to lose the MET-CLN2 plasmid
(unpublished data). Thus, in a 26CLN2 strain, neither RME1 nor
MET-CLN2 is required for suppression; the suppressors must act
by de-repressing the native CLN2 locus.
These results establish that Stb1, Sin3, and Rpd3, like Whi5,
play a role in the repression of SBF target genes. However, they do
not establish whether Stb1, Sin3, and Rpd3 are additional
components of the Whi5 pathway (i.e., Whi5 might act by
attracting the Rpd3 complex), or whether some or all of these new
repressors constitute the second pathway that allows whi5 mutant
cells to respond to CLN3. To address this, we did epistasis analysis.
We constructed double mutants with whi5 (i.e., stb1 whi5, sin3 whi5,
rpd3 whi5), and asked whether any of these double mutants would
reduce or eliminate responsiveness to CLN3 (which would indicate
that the new repressors are in the second new pathway). Unlike
either of the single mutants, a whi5 stb1 double mutant is almost
nonresponsive to CLN3 (Figure 1). Thus STB1 likely defines a
second pathway by which CLN3 controls activity of SBF.
Epistasis analysis of rpd3 and its targeting subunit sin3 with whi5
and with stb1 gave complex results. The whi5 sin3 and the whi5 rpd3
mutants are still responsive to CLN3 with respect to size (Figure 1,
fifth and sixth panels), although the whi5 sin3 mutant does not
show any responsiveness with respect to budding. This suggests
that sin3 (in particular) and rpd3 may be partially but not fully
blocking the Stb1 pathway. But stb1 sin3 double mutants are
responsive to CLN3 (unpublished data), suggesting that the sin3
mutation is not fully blocking the Whi5 pathway. Previous
experiments have established links between Sin3, Rpd3, and
Stb1 [29,31]. We feel there are several alternative interpretations
of these data (see Discussion), the most likely being that Whi5,
Stb1, and Swi6 all interact to some extent with the Rpd3 histone
deacetylase complex. Consistent with this, Huang, Kaluarchchi
and Andrews have recently found an association between Whi5
and Rpd3 by co-immunoprecipitation (personal communication).
Figure 2. Suppressors of cln3 bck2. Various mutations were tested for ability to suppress lethality of a cln3 bck2 rme1 {MET-CLN2} strain on
+methionine medium. The parental strain (N497) is cln3 bck2 rme1 {MET-CLN2}; other strains (top to bottom: N452, N453, N451, N499, and N454) have
one additional mutation as indicated. Serial 4-fold dilutions were spread on 2methionine (where MET-CLN2 is expressed) or +methionine (where
MET-CLN2 is repressed). The HOS3 gene encodes a histone deacetylase, but this histone deacetylase was not identified in our suppressor screen and
serves as a negative control.
doi:10.1371/journal.pbio.1000189.g002
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and Rpd3 and Sin3 Are Removed in a CLN3-Dependent
Fashion
To further characterize the mechanisms by which Cln3promotes
transcription of SBF target genes, we used chromatin immunopre-
cipitation (ChIP) to build on the earlier work of Cosma, Nasmyth,
and coworkers [9,10] and observe events at the CLN2 promoter (an
important SBFtarget gene) as a function of Cln3abundance.Thisis
a challenging goal, since once cells have passed through Start, they
repress transcription of SBF target genes by additional mechanisms
[37]. Thus activation of SBF target genes under normal conditions
is transientanddifficulttocharacterize.Therefore,we constructed a
strain with genotype GAL-CLN3 bck2 cdc34-2 (i.e., CLN3 is expressed
from the GAL promoter). This strain can be synchronized in G1
before Start by growing in raffinose (i.e., without galactose, CLN3
expression is off, its target G1 cyclins CLN1 and CLN2 are not
expressed, and Start does not occur). When these G1 cells are then
switched to raffinose plus galactose medium at 37uC (the restrictive
temperature for the cdc34-2 mutation), CLN3 is turned on, SBF
targets are transcribed, but progress through the cell cycle (and the
consequent repression of SBF targets) does not occur because of the
cdc34-2 defect. Thus we can follow a cell population from a state
where SBF genes are fully repressed in all cells (in raffinose medium)
to a state where SBF genes are fully induced in all cells (in galactose
medium at 37uC).
Figure 4 shows the fate of some relevant proteins at the CLN2
promoter as a function of CLN3 expression. As expected from
previous work, Swi4 is at the SBF binding sites of the CLN2
promoter at all times [10–12], regardless of the presence or
absence of CLN3. RNA polymerase II is initially absent, but is
recruited to the TATA box of CLN2 (and to the TATA box of
BBP1, the divergently transcribed, SBF-controlled gene at the
other end of the intergenic region) 5 to 10 min after induction of
CLN3. Northern analysis shows that the production of CLN2
mRNA almost exactly coincides with recruitment of RNA pol II
(Figure 4). Previous studies have shown that this recruitment of
RNA pol II depends on Cdc28 kinase [9]. Stb1 is also found near
the SBF binding sites, and its presence is not affected by induction
of Cln3. Finally, Whi5, Sin3, and Rpd3 are all initially present
near the SBF binding sites on the CLN2 promoter, and each of
these proteins is lost after CLN3 is induced. Consistent with the
relative early and CLN3-dependent loss of Rpd3, Huang,
Kaluarchchi and Andrews have recently found that CLN3 can
reduce the amount of the Whi5-Rpd3 complex seen by co-
immunoprecipitation (personal communication).
Several of these results were also repeated, with the same results,
on the YOX1 promoter, which is also regulated by CLN3 and is
coregulated with CLN2 (Figure 4C).
Surprisingly, the loss of the repressive proteins is not obvious
until 5 to 15 min (for Sin3 and Rpd3), or 15 to 25 min (for Whi5)
after CLN3 induction; that is, recruitment of RNA pol II, and the
appearance of CLN2 transcript, occur before all the repressive
proteins are lost. There are at least three nonexclusive explana-
tions for these kinetics: first, it could be that the repressive proteins
are quickly phosphorylated and thereby inactivated as repressors
by the Cln3-Cdc28 kinase complex; loss of the proteins from the
promoter could be a secondary event. Second, it could be that
Cln3-Cdc28 is promoting some positive event that directly induces
transcription, and this precedes full loss of the repressive activities.
Perhaps phosphorylation of Stb1 or Swi4 or Swi6, for instance,
could directly promote transcription even in the presence of
repressors. Third, there could be some systematic bias in our ChIP
assay such that it is easier to see new proteins arriving at CLN2
than to see old proteins leaving. Additional experiments will be
required to distinguish these possibilities.
Figure 3. Analysis of CLN1 and CLN2 expression in the cln3 bck2 stb1 and cln3 bck2 whi5 strains. qPCR was used to measure the expression
of CLN1 and CLN2 in two of the suppressor strains. The parental strain is cln3 bck2 rme1 {MET-CLN2} (N497), and the two suppressor strains have, in
addition, stb1 (N451) or whi5 (N499), as indicated. (A) The left panel shows quantitation of CLN1 and CLN2 mRNAs by qPCR, in the absence (2met) or
presence (+met) of methionine. (B) The right panel shows the PCR products from (A) separated by agarose gel electorphoresis. The plasmid-borne
allele of CLN2 is CLN2-NLS-I; it carries a tag that increases the length of the mRNA and the PCR product, allowing expression of genomic CLN2 to be
distinguished from expression of plasmid-borne MET-CLN2-NLS-I. This demonstrates that the increased CLN2 expression caused by stb1 and whi5 is
specific for the genomic copy of CLN2. The qPCR measurement in (A) includes both forms of CLN2, suggesting that the increased expression of
genomic CLN2 in the stb1 and whi5 mutants is about 3-fold. The primers for amplification of ACT1 flank the ACT1 intron, yet only the mRNA-specific
band was obtained, showing that no DNA was present in the RNA preparation. Error bars show the standard error of the mean.
doi:10.1371/journal.pbio.1000189.g003
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above allowed us to look at events at the CLN2 promoter in a way
that is powerful and sensitive, but also contrived. Therefore, we
repeated some of the experiments in a different genetic
background. We used a strain carrying a cdc20 mutation and a
galactose inducible CDC20 gene (GAL-CDC20) to arrest cells at the
cdc20 block (mitosis; pre-anaphase), then release them synchro-
nously. Although this approach is less sensitive than the GAL-CLN3
bck2 cdc34-2 method, we were able to reproduce several of the
main results. For example, Figure 4E shows Sin3 being recruited
to the CLN2 promoter early in G1, then leaving as cells exit G1 (in
this experiment, budding begins at about 50 min).
We began to characterize the binding dependencies of some of
the proteins at the CLN2 promoter (Figure 5; Table 1); one obvious
question is whether binding of the Sin3-Rpd3 complex depends on
Whi5 or Stb1. Sin3 still binds to the CLN2 promoter in a whi5
mutant and also in an stb1 mutant, and also in a whi5 stb1 double
mutant. To see if Sin3 binding was SBF dependent, we used both
swi4 and swi6 mutations, and found that the association of Sin3
with the CLN2 promoter is dependent on SWI6 (p=4 610
23), but
only slightly if at all dependent on SWI4 (Figure 5; Table 1).
Presumably in the absence of Swi4, MBF (Mbp1+Swi6) is binding
to the CLN2 promoter and recruiting Sin3-Rpd3. The dependence
of Rpd3 binding on Swi6 correlates with previous findings that
Swi6 contains Cln3-modulated repressive domains [19]; these
could be the regions responsible (directly or indirectly) for
recruiting the Rpd3 complex. Stb1 and perhaps Whi5 could
further influence the recruitment or activity of the Sin3-Rpd3
complex.
Robert et al. [35] previously found that Rpd3 associates with
the promoters of CLB6 and PCL1, which are regulated by SBF and
by MBF. In contrast to our finding of Swi6 but not Swi4
dependence at the CLN2 promoter, Robert et al. found that the
association of Rpd3 with CLB6 and PCL1 required both Swi6 and
Swi4. The reason for the difference between the studies with
respect to the requirement for Swi4 is unclear, but in any case both
studies agree that SBF is involved in the recruitment of the Rpd3
complex.
Cln3 Is Found at the CLN2 Promoter
While it is clear that that Cln3-Cdc28 protein kinase complex
somehow promotes the loss of Sin3, Rpd3, and Whi5 from the
CLN2 promoter, it is not clear how directly Cln3 acts, or exactly
what proteins the Cln3-Cdc28 complex phosphorylates. We found
that Cln3 co-immunoprecipitates with the Swi6 component of
SBF, and that this co-immunoprecipitation depends on Swi4
(Figure 6). Thus, there is a relatively direct interaction between
Cln3 and SBF. ChIP showed that Cln3 is found on the CLN2
promoter close to the SBF binding sites (Figure 6), the same
location as SBF, Whi5, Sin3, Stb1, and Rpd3. Cln3-Cdc28 is thus
in a location suitable for the direct phosphorylation of these and
other associated proteins. Both Whi5 and Stb1 have a very high
density of consensus phosphorylation sites for the Cdc28 kinase
(2.7 or 2.6 consensus and near-consensus sites per 100 amino
Figure 4. Proteins at the CLN2 promoter. (A) Map of the CLN2
promoter, showing the location of the up, sbf, and dwn probes in the
BBP1-CLN2 intergenic region. The sbf probe overlaps the consensus SBF
binding sites. The dyn probe is in the middle of the DYN1 open reading
frame, several kilobases from the nearest promoter. On the right is
shown the relative order of these probes on gels; i.e., the dyn probe has
the lowest mobility, and the dwn probe the highest mobility. (B)
Proteins at the CLN2 promoter as a function of CLN3 induction. GAL-
CLN3 expression was induced (left) or not (right) by the addition of
galactose. Samples were taken from 0 to 30 min. Proteins were cross-
linked to DNA and processed as described, and TAP-tagged proteins
(from strains HWL61, HWL59, HWL51, HWL62, HWL77, and HWL128)
were immunoprecipitated. Coprecipitated DNA fragments were iden-
tified by PCR using probes amplifying fragments described above in (A).
Whole cell extract (WCE) was also amplified, as a positive control.
Samples (HWL49) from cells lacking any TAP-tagged protein were
processed as a negative control (No tag). The parental strain was
HWL49, with partial genotype GAL-CLN3 bck2 cdc34-2. (C) As (B), but
TAP-tagged Sin3 is being assayed by ChIP at the YOX1 promoter,
instead of at the CLN2 promoter. (D) Kinetics of induction of the CLN2
mRNA, by Northern analysis. 5S RNA serves as a loading control. (E) GAL-
CDC20 cdc20 SIN3-TAP cells were arrested in M-phase in glucose, then
GAL-CDC20 was induced at 0 time with galactose medium. The amount
of Sin3-TAP associated with the CLN2 promoter was assayed during a
timecourse. Budding initiates at about 50 min.
doi:10.1371/journal.pbio.1000189.g004
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likely substrates for Cln-Cdc28 kinase [20,21,34]. Swi6 and Swi4
also have multiple potential Cdc28 phosphorylation sites, and
could be Cln3-Cdc28 substrates in vivo.
Cln3 May Be Titrated by SBF and Its Binding Sites
The fact that Cln3 is at the CLN2 promoter raises another issue.
Yeast has 100 to 200 genes under the control of SBF and the
related transcription factor MBF, and these genes typically have
two, three, or more SBF/MBF binding sites each. Thus the total
number of functional SBF and MBF binding sites in the cell is in
the vicinity of 400. But the average number of Cln3 molecules in a
haploid cell is only about 100 [38]. Of course there is considerable
uncertainty in these measurements, but nevertheless it is likely that
cellular SBF/MBF binding sites are in excess over Cln3.
This excess of binding sites could provide a basis for the critical size
requirement for Start. As cells grow in mass, ribosome content, and
protein synthetic capacity, they contain increasing numbers of Cln3
molecules [7]. Indeed, growth in the number of Cln3 molecules may
be faster than the growth in mass [39]. Yet the number of SBF
bindingsitesisfixed byDNAcontent.Thus,asthecellgrows,itcould
titrate an increasing number of Cln3 molecules against a fixed
number of SBF binding sites, which are initially in excess. At some
ratio, the bound Cln3 could activate SBF, resulting in Start.
If this model were correct, then an increase in the number of
SBF sites in the cell would increase the requirement for Cln3, and
so would cause an increase in cell size at Start. We transformed
otherwise wild-type cells with a high copy number plasmid
containing four tandem, perfect SBF binding sites (an SBF binding
site is called an ‘‘SCB’’). Since the plasmid has a copy number of
about 30, this provides about 120 extra sites, or roughly a 20%
increase over the wild-type number of sites. We used elutriation to
collect small G1 phase cells carrying the 46SCB plasmid (or a
control plasmid lacking the 46SCB insert), then let these cells
grow. We assayed cell volume, and the percentage of budded cells
as an assay of Start. As shown in Figure 7, cells lacking the 46SCB
insert went through Start at about 32 fl, while cells containing the
46SCB insert went through Start at about 38 fl, roughly a 20%
increase. This experiment is consistent with the idea that the cell is
Figure 5. Dependency analysis. (A) ChIP analysis of proteins at the
CLN2 promoter in various mutants. Cells (left panel: S288c, HWL99,
HWL110, OBS1, and HWL117; right panel S288c, HWL110, HWL119, and
OBS5) were CLN3 BCK2 CDC34 in exponential growth. The TAP-tagged
protein being assayed is indicated, as is any additional mutation in the
strain. The arrowhead (.) indicates the band containing the SBF
binding sites. Other bands are as drawn in Figure 4A. (B) ChIP analysis of
proteins at the CLN2 promoter in various mutants. As in Figure 4A, but
with a different selection of mutants. The arrowhead indicates the band
containing the SBF binding sites. (C) ChIP analysis of Sin3-TAP at the
CLN2 promoter in wild-type, swi4, swi6, and untagged (negative control)
strains. Ten independent experiments were done for each of the four
genotypes. Results for all 40 experiments were obtained and tested
statistically after ‘‘blinding’’ the samples (Table 1). The two median-most
experiments for each of the four genotypes are shown here. The ratio of
the intensity of the SBF band (arrowhead) to the sum of the intensities
of the upper two bands (‘‘dyn’’ plus ‘‘up’’) is shown at the bottom of
each gel lane.
doi:10.1371/journal.pbio.1000189.g005
Table 1. Binding of Sin3 to the CLN2 promoter in swi4 and
swi6 mutants: p-values.
Strain WT swi4 swi6 Negative Control
WT 0.5 0.004 0.0003
swi4 0.0008 0.00001
swi6 0.1
p-Values for a test of a difference of means for ChIP analysis of the CLN2
promoter fragment containing the SBF sites in strains containing tagged Sin3.
The strains are wild-type (WT), swi4,a n dswi6 strains all carrying tagged SIN3,
and an untagged SIN3 strain as a control. The experiment was done ten
independent times in each strain. For each experiment, PCR-amplified DNA
from ChIP was placed in a tube with a coded label by one investigator (HYW),
and given to a second investigator (LBC). PCR fragments were separated by gel
electrophoresis, and the ratio of the ‘‘sbf’’ band to the mean of the ‘‘up’’ and
‘‘dyn’’ bands (see Figures 4 and 5) was determined using image analysis
software. Once ratios were determined, the label code was broken, and ratios
were assigned to their genotypes. One-tailed t-tests were done to calculate p-
values of the differences of the means of the logarithms of the ratios (Log ratios
were used so as to produce a normal distribution). These p-values are shown
above. For example, Sin3 does not appear to ChIP to the CLN2 promoter in a
swi6 mutant, and the difference between the swi6 mutant and the wild-type in
this regard has a p-value of 4610
23. Two typical (median) experiments were
chosen from each of the ten sets of experiments and shown in Figure 5.
doi:10.1371/journal.pbio.1000189.t001
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the number of available SBF binding sites.
This experiment was done using several independent pairs of
transformants a total of five times (i.e., five pair-wise comparisons). In
every case, the strain with the 46SCB plasmid had a larger critical
size than the strain with the control plasmid. The differences in
critical size in the five experiments were 2.6, 3.7, 6.1, 9.2, and 10.6 fl,
with a mean of 6.4 fl (p,0.005 for a test of the hypothesis that the
difference is 0 using a paired sample one-tailed Student’s t-test; also
statistically significant by nonparametric tests). The experiment
shown in Figure 7 is the median experiment, with a 6.1 fl difference.
One issue with this titration experiment is that the 46SCB
plasmid might increase critical size through some irrelevant
pathology. If this were so, then the 46SCB plasmid would cause
roughly the same percentage increase in size regardless of any
changes we might make to the CLN3/WHI5/SBF system. A
second issue is that even if the activator titration model is correct,
it is not clear what activator is being titrated; it might be Cln3, but
Swi4, Swi6, and even Stb1 are also possibilities.
To address these issues, we first repeated the experiment in a
strain carrying two copies of CLN3 (26CLN3; a second copy is
tandemly integrated at the wild-type CLN3 locus). If the titration
hypothesis is correct, then the second copy of CLN3 should largely
compensate for the ,20% increase in SCB sites. Indeed, the
increased size caused by the 46SCB plasmid in a 26CLN3
background is only 0.6 fl (Figure 7). A 26CLN3 46SCB strain had
almost exactly the same size as a wild-type (i.e., 16CLN3) strain
bearing the control plasmid. (We note that a second copy of CLN3
causes only ,10% decrease in critical size in a wild-type strain
[38]. Presumably when Cln3 is sufficiently abundant, some other
molecule becomes limiting for Start.)
In addition, we did the titration experiment in a cln3 deletion
strain. If the effect of the 46SCB plasmid is irrelevant pathology,
then in the cln3 strain, the same irrelevant pathology should occur,
and the 46SCB plasmid should again increase critical size. On the
other hand, if Cln3 is the activator being titrated, then in the cln3
strain, the 46SCB plasmid should have no effect on critical size,
since it has nothing to titrate. In fact, to our great surprise, we got
neither of these results. Instead, cln3 cells actually got smaller when
we added the 46SCB plasmid (Figure 7). This surprising result
was confirmed with two additional experiments (unpublished
data), using independently constructed strains. (The experiment
shown has the median difference of the three experiments.) This
result tells us two things: first, the results are not irrelevant
pathology, because the results change in a specific way with
changes in the CLN3/WHI5/SBF system. Second, a likely
Figure 6. Cln3 associates with SBF and ChIPs to the CLN2 promoter. (A) Cln3 co-immunoprecipitates with Swi6. Strains (HWL72, HWL112,
HWL130) with various combinations of CLN3 or CLN3-FLAG (pCM273), SWI6 or SWI6-Myc,o rSWI4 or swi4, were grown and extracts made. In the left
half of (A, these extracts were tested for the presence of the FLAG-tagged Cln3 and the Myc-tagged Swi6 by Western blotting with Anti-FLAG or Anti-
Myc antibody). In the right half, proteins were immunoprecipitated with Anti-Myc antibody (directed against Swi6-Myc), and then these
immunoprecipitates were tested by Western blotting for the presence of Swi6-Myc and Cln3-FLAG. (B) As 6A, except that the immunoprecipitation is
done with the anti-FLAG antibody, followed by Western analysis with the anti-Myc antibody. (C) A ChIP experiment as in Figure 4B, for association of
Cln3-TAP (HWL49, HWL63) with the CLN2 promoter.
doi:10.1371/journal.pbio.1000189.g006
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(otherwise a deletion of CLN3 would make no difference), but that
the 46SCB plasmid is also titrating repressors. That is, Cln3 is
most limiting (so high copy 46SCB causes bigger cells in a wild-
type background), and repressors are next most limiting (so when
there is no Cln3 anyway, then the high copy 46SCB plasmid
decreases size by titrating repressors).
If this is true, then a strain that lacks both Cln3 and also the
repressors (Whi5 and Stb1) should not be affected by high copy
46SCB. And this proves to be the case (Figure 7, bottom right); a
whi5 stb1 cln3 strain is not affected by the high copy 46SCB
plasmid. Note that the whi5 stb1 mutant is not responsive to CLN3
(Figure 1); the fact that it is also not responsive to extra SCBs is the
expectation from the titration model.
The whi5 stb1 cln3 strains shown in Figure 7 lack all known
regulationoftheCln3 size controlpathway.Yet, thesestrainshavea
size at budding similar to that of wild-type, and have a sigmoidal
budding curve suggesting a dependence of budding on size. That is,
although the best-characterized size control mechanism is missing,
the cells apparently exhibit some form of size control. This suggests
the existence of a redundant size control mechanism. The same
phenomenon has been observed previously in different circum-
stances [39], where the redundant size control was attributed to a
translational mechanism. In addition, Jorgensen et al. [22] found
many size control mutants that were not in the CLN3 pathway.
Discussion
Here we have found that the Whi5 pathway is not the sole link
between Cln3-Cdc28 and SBF activity. We have found several
mutants that, like whi5, relieve the repression of SBF, and render
its activity somewhat independent of Cln3-Cdc28. These mutants
include chd1, hda2, pho23, sin3, rpd3, and stb1. Of these, pho23, sin3,
stb1, and rpd3, are members of, or have been physically linked to,
the Rpd3 histone deacetylase complex, a repressive histone
deacetylase orthologous to mammalian HDAC1.
Although we do not know the exact relationship between these
proteins and Whi5, we have found that the stb1 mutation is
synergistic with whi5; that is, in the context of a bck2 mutation, the
stb1 whi5 double mutant, unlike either single mutant, has little
ability to respond to Cln3-Cdc28. Thus in some sense Stb1
identifies a pathway for regulating SBF that is separate from the
Whi5 pathway.
While we have identified STB1 in a screen for repressors of SBF,
others have previously identified STB1 as an activator of SBF or
MBF [33,34]. While paradoxical at first sight, it is quite common
for transcription factors to have both positive and negative roles in
transcription. An example is Fkh2, which collaborates with Mcm1
and Ndd1 transcription factors, and with Clb-Cdc28 kinase
activity, to regulate mitotic genes. In this context, Fkh2 appears to
be an activator in late G2 and mitosis, but a repressor at other
times [40–44]. Similarly, we imagine that Stb1 helps repress SBF
in the absence of Cln3 and Bck2 (the situation in which we found it
as a repressor), but helps activate SBF in the presence of Cln3 or
Bck2 (the situation in which it was characterized as an activator).
Consistent with this, cell cycle expression analysis of stb1 mutants
shows that target genes are less repressed at troughs, and less
induced at peaks; i.e., they are less regulated and more constitutive
(e.g., Figure 3 in [34]). The fact that CLN3 can induce expression
of CLN2 even before Sin3, Rpd3, and Whi5 are lost from the
Figure 7. Cln3 may be titrated by SBF binding sites. Cells (BF305-15d, HWL148, HWL145, and HWL146) were transformed with an empty vector
(pBA70, grey line) or the same vector carrying an insert with four tandem copies of an SBF binding site (‘‘pSCB’’) (pMT3579, black line). Cells were
grown to early log phase, and fractionated by centrifugal elutriation. Fractions containing small unbudded cells with a mode volume of about 20 fl
were chosen and re-inoculated. Cell size (x-axis, in fl) and budding (y-axis, percent) were followed with time. The median experiment of five total wild-
type experiments is shown in the upper left. ‘‘Critical size’’ was defined to be the size (in fl) at which 50% of the cells became budded. This critical size
is shown next to each curve.
doi:10.1371/journal.pbio.1000189.g007
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expression of CLN2 depends on activation, perhaps via Stb1,
rather than on loss of repression.
If Stb1 is both a repressor and an activator, then some of our
assays may preferentially see one of these activities, and some may
see the other. Presumably it is the lack of repression by Stb1 that
allows the stb1 mutation to suppress the lethality of the cln3 bck2
mutant. But the cell size assay for responsiveness to CLN3 (Figure 1)
may be more sensitive to Stb1 as an activator; in particular, the
synergistic defect between whi5 and stb1 may be due to the lack of
repression in the whi5 mutant, plus the lack of activation in the stb1
mutant. We note that the combinations of mutations that include
stb1 tend to have relatively large cell sizes after induction of GAL-
CLN3 (Figure 1), perhaps showing that STB1 is needed for full
induction of CLN2.
While Whi5 and Stb1 seem to define two pathways of regulation
of SBF, it is still unclear how the Sin3-Rpd3 histone deacteylase
complex is recruited to the CLN2 promoter. Previously, the Rpd3
complex has been linked to Stb1 [29,31]. More recently, Huang,
Kaluarchchi and Andrews have found evidence for an association
between Rpd3 and Whi5 (personal communication). Despite these
associations, we found that even whi5 stb1 double mutants had at
least some Sin3 (and so presumably Rpd3) at the CLN2 promoter,
whereas swi6 mutants had little or no Sin3. Thus although one
could imagine various relationships between these proteins, one
model is that SBF has some ability to recruit each of Whi5, Stb1,
and Sin3-Rpd3, but that these proteins in addition interact with
each other (Figure 8). Later, in a size- and growth-dependent
fashion, Cln3-Cdc28 also joins the complex, and phosphorylates
Whi5 and Stb1 and probably Swi6 and possibly Swi4. This causes
the loss of the Rpd3 complex; a somewhat slower loss of Whi5
(Figure 4); and perhaps allows phosphorylated Stb1 to help
activate transcription (Figure 8). That Swi6, along with Whi5 and
Stb1, is probably a target of Cln3-Cdc28 phosphorylation is
strongly suggested by the fact that over-expression of a mutant
Whi5 lacking CDK phosphorylation sites is lethal in a mutant
where Swi6 is likewise lacking CDK phosphorylation sites [20,45].
The involvement of Swi6 as a likely target of Cln3-Cdc28, and as a
recruiter of Sin3-Rpd3, may explain why even whi5 stb1 double
mutants seem to have some slight residual Cln3-responsiveness
(Figure 1); that is, this residual responsiveness could be through
direct phosphorylation of Swi6.
Results reminiscent of ours with regard to Sin3 and Rpd3 were
previously obtained by Veis et al. [36], who found that Sin3 and
Rpd3 associate with the promoter of the CLB2 gene, which
encodes a mitotic cyclin. Although CLB2 is most highly expressed
in G2/M, the association of Sin3 and Rpd3 with the CLB2
promoter was lost in late G1, at about the same time we see loss of
Sin3 and Rpd3 from the CLN2 promoter. Veis et al. interpreted
their results in terms of the association between Sin3/Rpd3 and
the Fkh2 (forkhead) transcription factor, and suggested that this
association was sensitive to Start. However, we note that CLB2,
despite being most strongly up-regulated in G2/M, is a client of
SBF as well as a client of Fkh2. The CLB2 promoter contains at
least three clustered SBF/MBF binding sites, at least two of which
are conserved in other species of yeast [46]. In ChIP experiments,
CLB2 is a target of SBF or MBF binding [47,48]. Thus the loss of
Sin3/Rpd3 from the CLB2 promoter in late G1 as seen by Veis
and coworkers could involve SBF at the CLB2 promoter, and so
could be related to the phenomenon we see at the CLN2 promoter.
Another protein we find at the CLN2 promoter is Cln3.
However, demonstrating this association was difficult, and
required a special genetic background and over-expression of
Cln3. Part of the difficulty in ChIPing Cln3 to the CLN2 promoter
is presumably because Cln3 is a nonabundant protein, and does
not bind DNA directly. But in addition, Cln3 may not be a
stoichiometric member of the complex. Instead, it may bind
weakly and transiently, phosphorylate its substrate(s), and leave.
The two proteins we find to be essential for Cln3 responsiveness,
Whi5 and Stb1, are both very likely substrates of Cln-Cdc28
[20,21,34].
Cln3 is present at only about 100 molecules of protein per cell,
and yet there are in the vicinity of 400 functional binding sites for
SBF and the related factor MBF. The fact that Cln3 is sub-
stoichiometric with respect to binding sites could provide a partial
solution to the size control problem: Perhaps the amount of Cln3
in the cell, which is a function of cell size and growth rate, is
titrated against the number of binding sites. And indeed we found
that cells containing extra SCBs had to grow to a larger size to
accomplish Start, and this effect could be compensated by one
extra dose of CLN3. Extra SCBs did not enlarge a cln3 null mutant,
and extra SCBs had no effect whatever on cln3 stb1 whi5 triple
mutants. These findings are all supportive of the titration model.
Even though larger G1 cells contain more Cln3 molecules than
smaller cells, the increase in Cln3 content with size is probably
quite moderate, possibly only linearly correlated with cell size.
Thus even at cell sizes adequate for Start, Cln3 may still be sub-
stoichiometric with respect to binding sites. Thus we imagine that
Figure 8. Model for regulation by Whi5, Stb1, and histone
deacetylase. The SBF complex (green) recruits Whi5 (blue) and Stb1
(grey). The SBF complex also recruits the repressive Rpd3 histone
deacetylase complex (black); this recruitment may be aided by Whi5
and/or Stb1. In a growth- and size-dependent way, the Cln3-Cdc28
kinase (orange-red) is recruited. This CDK phosphorylates Whi5 and
Stb1 and possibly Swi6, resulting in the loss of the Rpd3 complex and
the loss of Whi5. The transcriptional activation domain of Swi6 is
revealed, possibly aided by an activating function of phospho-Stb1.
doi:10.1371/journal.pbio.1000189.g008
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there will only be fractional occupancy of SBF sites, especially if
Cln3 is a weak and transient binder. But as the amounts of Cln3
rise, and are titrated against a fixed number of SBF sites, that
fractional occupancy will rise, until at some occupancy (i.e., at
some critical cell size), CLN2 and other targets are expressed, and
the cell passes through Start. The issue is, how to convert a
relatively small change in total Cln3 into a large change in
fractional occupancy, or, alternatively, how to convert a small
change in occupancy into a large effect?
Although we do not know the answers to either of these
questions, Ferrell and coworkers have described many mecha-
nisms by which such ‘‘super-sensitivity’’ can occur [49–56]. One
mechanism would use the fact that SBF target genes have multiple
SBF binding sites. Perhaps the binding of Cln3 to SBF is
cooperative; or perhaps the Cln3 molecules, once bound,
cooperate to do something else, such as phosphorylate a substrate.
Cooperativity of any kind between multiple sites will give
exponential sensitivity to Cln3 amounts, so this is one possible
mechanism. A second mechanism is multisite phosphorylation.
That is, perhaps the substrates of Cln3-Cdc28 have to be
phosphorylated at multiple sites, and this can only happen when
fractional occupancy of SBF sites by Cln3 is relatively high. Since
phosphorylation is in a dynamic equilibrium with dephosphory-
lation, a requirement for multisite phosphorylation (at, say, five
sites) imposes a super-sensitive threshold on the amount of kinase
required [52,57,58]. Multisite phosphorylation can give extreme
sensitivity to the amounts of a protein kinase [52,57,58]. A third
possible mechanism is to consider the relationship between the
complexes at the multiple SBF sites. There are three sites at CLN2;
if all three have repressive proteins, is enough Cln3 needed to fill
all three sites simultaneously, even though occupancy of any one
site is always transient? At any rate, although we do not know how
supersensitivity works in this situation, there are lots of ways it
could work in theory, as cited above.
There are remarkable parallels between the SBF/Cln3/
Whi5,Stb1/Rpd3 regulatory module in yeast, and the E2F-Dp/
Cyclin D1/Rb/HDAC1 regulatory module in mammalian cells.
To begin with, the cluster of regulated genes is highly conserved:
In S. cerevisiae [6], in the distantly related yeast S. pombe [59], in
mammalian cells [60], and probably in most or all other
eukaryotes, there is a highly conserved cluster of genes needed
for DNA replication, and expressed around the G1/S transition.
In both yeasts and mammals, the motifs regulating these genes
contain a core ‘‘CGCG’’ element. In both yeasts and mammals,
the transcription factors recognizing this element (SBF/MBF in
the yeasts, E2F-Dp in mammals) contain a DNA binding domain
with a ‘‘winged helix’’ fold [61–63]. There is no apparent
sequence homology between the yeast and mammalian DNA
binding domains, but the domain is small, the evolutionary
distance vast, and there are other examples where structure but
not sequence has been preserved across time.
In E2F-Dp, the transactivator is repressed by binding of Rb and
its family members. There are two mechanisms of repression [64–
70]. First, the transactivation domain is masked. Second, Rb
family members (but possibly not Rb itself-[69]) recruit mSin3B
and HDAC1 which deacetylate and otherwise modify chromatin
so as to be inhospitable towards expression. Here, we likewise
show that there are at least two pathways of regulation, one of
them involving recruitment of a histone deacetylase. In mammals,
the transactivation domain is unmasked when a cyclin-CDK
complex such as cyclin D-CDK4 phosphorylates Rb and family
members, disrupting binding to E2F-Dp, and allowing Sin3m and
HDAC1 to leave the chromatin. Similarly, in yeast, Cln3-CDK
phosphorylates Whi5 and probably Stb1. Whi5, Sin3, and Rpd3
all leave the chromatin. Interestingly, expression of the target gene
Cln2 precedes the loss of the repressive proteins, consistent with a
dominant activation, possibly due to Stb1. In any case, it is clear
that there are deep, well-conserved parallels between the SBF/
Cln3/Whi5,Stb1/Rpd3 regulatory module in yeast, and the E2F-
Dp/Cyclin D1/Rb/HDAC1 regulatory module in mammals. It is
possible that these modules have regulated the cluster of genes for
DNA synthesis since early in eukaryotic evolution.
Materials and Methods
Strains
Strains are shown in Table 2.
Cell Cycle Synchronization
For GAL-CLN3 cdc34-2 block and release experiments, cells
growing in YEP with 2% raffinose+2% galactose (YEPRG) at
25uC were arrested in G1 by washing with YEP+2% raffinose
(YEPR) and incubating in YEPR for four hours at 25uC. Cells
were then shifted to 37uC for 1 h, and then cultures were split in
two; one half remained in YEPR and to the other half galactose
was added to 2% final concentration. Both cultures were
incubated at 37uC and samples were taken every 5 min.
For elutriations, cells containing plasmids (pBA70 and
pMT3579) were grown in Synthetic Complete (SC) medium with
2% filter-sterilized sucrose as the carbon source. Small unbudded
G1 cells were isolated by centrifugal elutriation and grown in
preconditioned SC+2% sucrose at 30uC. Cell size distributions
were obtained on a Z2 Coulter Counter and budding indexes were
determined by counting cells. Bud counts were done ‘‘blind’’ on
randomized samples.
Immunoprecipitations, Northern, and Western blots
Immunoprecipitations and Northern and Western blots were
carried out essentially as described previously [71,72]. Cell lysates
were obtained by vortexing cell suspensions in lysis buffer (0.1%
NP40, 250 mM NaCl, 50 mM NaF, 5 mM EDTA, and 50 mM
Tris [pH 7.5]) in the presence of glass beads. Cell debris was
pelleted by centrifugation for 10 min at 4uC. Protein concentra-
tion in the lysate was determined by the DC protein assay (Bio-
Rad). Lysates typically contained 20–50 mg/ml of total protein.
For immunoprecipitation, 5 mg of cell lysate mixed with 2 mlo f
9E10 anti-Myc ascites fluid or 5 mg of anti FLAG antibody
(Sigma) were rotated for 1–2 h at 4uC. Immune complexes were
collected on protein A-Sepharose beads by rocking at 4uC for 1 h.
For detection of immunoprecipitated proteins, beads were pelleted
by very gentle, brief, low-speed centrifugation, washed four times
with lysis buffer, and boiled in protein sample buffer immediately
before SDS-PAGE.
ChIPs
Early exponential phase cells were collected and formaldehyde
was added to 1% final concentration. Cells were fixed at room
temperature for 15 min.Cross-linking wasquenchedbythe addition
of glycine to 125 mM. Cells were pelleted at 3,000 g for 5 min and
washed twice with ice-cold TBS (150 mM NaCl, 20 mM Tris-HCl
[pH 7.6]). To break cells, cell suspensions in lysis buffer (50 mM
HEPES-KOH [pH7.5], 140 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 0.1% sodium deoxycholate) were mixed with glass beads and
vortexed at 4uC for 45 min.Chromatin was sheared bysonication at
power 3 (W-380 Sonicator, Heat Systems-Ulrasonic, INC) ten times,
10 s each time, and tubes were kept on ice throughout sonication.
Cell debris was removed by maximal speed centrifugation for
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Protein concentration for each sample was determined by DC
protein assay (Bio-Rad). Immunoprecipitations were performed with
1 mg of extract. Lysates were rotated with 25 ml IgG Sepharose
beads at 4uC overnight. Immune complex beads were washed with
lysis buffer, lysis buffer 500 (50 mM HEPES-KOH [pH 7.5],
Table 2. Plasmids and strains.
Plasmid or Strain Name Genotype Source
Plasmids pBA70s CYC1::lacZ 2 micron URA3 M. Tyers/B. Andrews
pMT3579 SCB-lacZ 2 micron URA3 (‘‘pSCB’’) M. Tyers/B. Andrews
pCM273 TETp-CLN3-6FLAG CEN URA3 M. Aldea
Strains HWL49 background
HWL49 MATa leu2 ura3 trp1 his3 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 H. Wang
HWL51 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 SIN3-TAP
HWL59 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 RPO21-TAP
HWL61 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 SWI4-TAP
HWL62 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 RPD3-TAP
HWL63 GAL-CLN3-TAP::KanMX bck2::TRP1 cdc34-2
HWL77 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 WHI5-TAP
HWL128 GAL-CLN3::URA3 bck2::TRP1 cdc34-2 STB1-TAP
BF305-15d background
BF305-15d MATa leu2 his3 ura3 trp1 ade1 arg5,6 met14 B. Futcher
HWL145 cln3::LEU2
HWL146 cln3::LEU2 whi5::KanMX stb1::NAT1
HWL148 CLN3::URA3::CLN3
S288c background
S288c MATa mal gal2 flo8 R. Mortimer
HWL99 SIN3-TAP::KanMX whi5::NAT1
HWL110 SIN3-TAP::KanMX
HWL117 WHI5-TAP sin3::NAT1
HWL119 SIN3-TAP stb1::NAT1
W303 background
W303-1a MATa ade2 trp1 leu2 his3 ura3 can1-100 {psi+} R. Rothstein
HWL72 tTA::LEU2
HWL112 SWI6-13MYC::KanMX4 tTA::LEU2
HWL130 SWI6-13MYC::KanMX4 swi4::NAT1 tTA::LEU2
N497 cln3::ura3 bck1::TRP1 rme1::hisG N. Edgington
N499 cln3::ura3 bck1::TRP1 rme1::hisG whi5::KanMX
N451 cln3::ura3 bck1::TRP1 rme1::hisG stb1::KanMX
N452 cln3::ura3 bck1::TRP1 rme1::hisG sin3::KanMX
N453 cln3::ura3 bck1::TRP1 rme1::hisG rpd3::KanMX
N454 cln3::ura3 bck1::TRP1 rme1::hisG hos3::LEU2
BY4701/4702 background
OBS1 MATa his3 leu2 ura3 met15 WHI5-TAP Open Biosystems
OBS5 MATa his3 leu2 ura3 met15 STB1-TAP Open Biosystems
LC504 URA3-GAL-CLN3 bck2::KanMX stb1::KanMX whi5::KanMX L. Carey
LC517 URA3-GAL-CLN3 bck2::KanMX
LC518 URA3-GAL-CLN3 bck2::KanMX stb1::LEU2
LC520 URA3-GAL-CLN3 bck2::KanMX::HIS3 whi5::LEU2
LC521 URA3-GAL-CLN3 bck2::KanMX::HIS3 whi5::LEU2 rpd3::KanMX
LC523 URA3-GAL-CLN3 bck2::KanMX::HIS3 whi5::LEU2 hda2::KanMX
LC524 URA3-GAL-CLN3 bck2::KanMX::HIS3 whi5::LEU2 sin3::KanMX
Strains were created during this study unless otherwise indicated. LC strains are from crosses between BY4741 and BY4742 strains. They are his3 leu2 ura3 with MAT,
met15 and lys2 segregating.
doi:10.1371/journal.pbio.1000189.t002
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deoxycholate), and LiCl/detergent (0.5% sodium deoxycholate,
1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 10 mM Tris [pH 8.0])
twice for each buffer and washed once with cold TE. Bead washing
was performed at 4uC.DNA was eluted by incubating beads at 65uC
with elution buffer (10 mM EDTA, 1% SDS, 50 mM Tris.Cl
[pH 8.0]) for 10 min, and crosslinks were reversed by incubating
samples at 65uC overnight. PCR was carried out for 30 cycles and
products were separated using 2.4% agarose gels.
qReal Time-PCR
A SuperScript III Platinum SYBR green one-step q(real-time)
RT-PCR kit (Invitrogen) was used for the detection and
quantification of RNA. 5 ng RNA was used for the RT-PCR
reaction. Total RNA were purified with RiboPure-Yeast kit
(Ambion).
Asynchronous Cell Size
Cells were grown overnight in either YEPR or YEPRG so that
cell densities were between 1 and 2610
7 cells/ml. Cultures were
placed on ice, sonicated to separate mothers from daughters, and
cell sizes were measured on a Z2 Coulter Counter. Cells were then
photographed at 406 and brightness and contrast adjusted in
Adobe Photoshop. All data shown are from cells in the S288c
genetic background; cells in both the W303 and BF305
backgrounds were also tested, and gave identical results.
Genetic Suppression
Cells were grown overnight in SC-Met, sonicated briefly, and
1:4 serial dilutions were plated onto either SC-Met or SC+2m M
Met plates. Cells on SC-Met plates were grown for 3 d at 27uC
before being photographed, whereas cells grown on SC+2m M
Met plates were grown for 5 d at 27uC.
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